<DOC>
	<DOCNO>NCT00003634</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . It yet know whether give monoclonal antibody therapy effective placebo treat patient ovarian epithelial , fallopian tube , peritoneal cancer respond surgery chemotherapy . PURPOSE : Randomized phase II trial study effectiveness monoclonal antibody therapy treat patient residual disease stage III stage IV ovarian epithelial , fallopian tube , peritoneal cancer follow surgery chemotherapy .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Treating Patients With Residual Disease From Stage III Stage IV Ovarian Epithelial , Fallopian Tube , Peritoneal Cancer Following Surgery Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : I . Compare time disease relapse , survival , quality life patient stage III IV ovarian epithelial , tubal , peritoneal adenocarcinoma treat OvaRex monoclonal antibody B43.13 OR placebo follow complete clinical response primary therapy . II . Determine safety regimen patient . III . Assess immune response patient treat regimen . OUTLINE : This randomize study . Patients undergo laparotomy platinum base chemotherapy prior randomization . Patients randomize 1 2 treatment arm : Arm I : Patients receive OvaRex monoclonal antibody B43.13 IV day 0 . Treatment continue 4 , 8 , 20 , 32 , 44 , 56 week , every 3 month absence disease progression unacceptable toxicity . Arm II : Patients receive placebo IV day 0 . Placebo administration continue schedule arm I . Patients present relapse provide second line chemotherapy . Quality life assess begin study , 2 month , every 3 month thereafter . Patients follow every 3 month . PROJECTED ACCRUAL : A total 400 patient ( 200 per arm ) accrue study .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage III IV ovarian epithelial , tubal , peritoneal adenocarcinoma Must complete clinical response primary therapy consist surgical debulking platinum base chemotherapy Elevated CA 125 ( great 35 U/mL ) prior surgery ( presurgical CA 125 measurement available , patient must serum CA 125 least 100 U/mL strong tumor tissue expression ) Must residual disease ( visible palpable ) completion stag laparotomy ( IIIB IIIC microscopic disease ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Karnofsky 60100 % Life expectancy : At least 6 month Hematopoietic : Hemoglobin least 8.0 g/dL Lymphocyte count least 300/mm3 Neutrophil count least 1,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal Renal : Creatinine great 1.6 mg/dL PRIOR CONCURRENT THERAPY : Biologic therapy : At least 6 week since prior immunotherapy No prior murine monoclonal antibody diagnostic therapeutic purpose Chemotherapy : No 1 prior regimen chemotherapy ( change chemotherapy agent permit primary therapy provide change consider part initial chemotherapy regimen ) At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior abdominal , abdominopelvic , pelvic radiotherapy Surgery : At least 4 week since prior surgery No 1 interval debulking procedure</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>